Pfizer Inc (PFE)

PFE on New York Consolidated

29.45USD
27 Aug 2014
Price Change (% chg)

$-0.04 (-0.12%)
Prev Close
$29.49
Open
--
Day's High
--
Day's Low
--
Volume
5,546,768
Avg. Vol
23,260,548
52-wk High
$32.96
52-wk Low
$27.81

PFE

Chart for PFE

About

Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The Company manages its operations through five segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health, and Consumer Healthcare. The Company’s diversified global healthcare portfolio includes human... (more)

Overall

Beta: 0.68
Market Cap (Mil.): $186,992.00
Shares Outstanding (Mil.): 6,340.86
Dividend: 0.26
Yield (%): 3.53

Financials

  PFE Industry Sector
P/E (TTM): 18.60 32.39 33.40
EPS (TTM): 1.59 -- --
ROI: 6.80 17.97 17.27
ROE: 13.38 18.61 18.02
Search Stocks

Pfizer to test Xalkori lung cancer drug with Merck immunotherapy

- Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck & Co's experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy.

26 Aug 2014

RPT-UPDATE 2-Pfizer to test Xalkori lung cancer drug with Merck immunotherapy

Aug 26 - Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck & Co's experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy.

26 Aug 2014

UPDATE 2-Pfizer to test Xalkori lung cancer drug with Merck immunotherapy

Aug 26 - Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck & Co's experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy.

26 Aug 2014

Pfizer to test Xalkori lung cancer drug with Merck immunotherapy

Aug 26 - Pfizer Inc on Tuesday said it will test its Xalkori lung cancer drug with Merck & Co's experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy.

26 Aug 2014

Roche to buy U.S. biotech firm InterMune for $8.3 billion

LONDON/ZURICH - Roche Holding AG has agreed to buy U.S. biotech company InterMune Inc for $8.3 billion in cash, marking the latest multibillion-dollar deal in a consolidating pharmaceutical sector.

24 Aug 2014

UPDATE 3-Roche to buy U.S. biotech firm InterMune for $8.3 bln

* Consensus 2019 sales for InterMune lung drug $1.04 bln (Adds comments from Roche CEO, analyst)

24 Aug 2014

FDA approves use of Eliquis to treat leg, lung clots

- Bristol-Myers Squibb Co and Pfizer Inc on Thursday said U.S. regulators have approved an expanded use for their Eliquis blood clot preventer, to treat blood clots in the legs and lungs.

21 Aug 2014

UPDATE 1-FDA approves use of Eliquis to treat leg, lung clots

Aug 21 - Bristol-Myers Squibb Co and Pfizer Inc on Thursday said U.S. regulators have approved an expanded use for their Eliquis blood clot preventer, to treat blood clots in the legs and lungs.

21 Aug 2014

FDA OKs use of Eliquis to treat leg, lung clots

Aug 21 - Bristol-Myers Squibb Co and Pfizer Inc on Thursday said U.S. regulators have approved an expanded use for their Eliquis blood clot preventer, to treat dangerous blood clots in the legs and lungs.

21 Aug 2014

Pfizer back for AstraZeneca? Year-end move seen most likely

LONDON - Shares in drugmaker AstraZeneca have climbed more than 7 percent this week, fueled by speculation of renewed takeover interest from Pfizer, following an abortive $118 billion (71 billion pounds) takeover attempt in May.

21 Aug 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $103.05 -0.17
Novartis AG (NOVN.VX) CHF81.90 -0.40
Merck & Co., Inc. (MRK.N) $60.11 -0.17
Roche Holding Ltd. (ROG.VX) CHF266.40 -1.80
Abbott Laboratories (ABT.N) $42.35 -0.25
Bayer AG (BAYGn.DE) €95.41 -2.28
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €82.70 -0.69
AstraZeneca plc (AZN.L) 4,473.25p +24.00
GlaxoSmithKline plc (GSK.L) 1,465.00p +2.00

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks